Specialty preference for cardiovascular prevention practice in the Southeast US and role of a preventive cardiologist.

dc.contributor.author

Ponir, Cynthia

dc.contributor.author

Seals, Austin

dc.contributor.author

Caldarera, Trevor

dc.contributor.author

Ip, Edward H

dc.contributor.author

German, Charles A

dc.contributor.author

Taylor, Yhenneko

dc.contributor.author

Moore, Justin B

dc.contributor.author

Bosworth, Hayden B

dc.contributor.author

Shapiro, Michael D

dc.contributor.author

Pokharel, Yashashwi

dc.date.accessioned

2023-11-07T14:49:57Z

dc.date.available

2023-11-07T14:49:57Z

dc.date.issued

2023-10

dc.date.updated

2023-11-07T14:49:56Z

dc.description.abstract

Introduction

Cardiovascular disease (CVD) prevention is practiced concurrently by providers from several specialties. Our goal was to understand providers' preference of specialties in CVD prevention practice and the role of preventive cardiologists.

Materials and methods

Between 11 October 2021 and 1 March 2022, we surveyed providers from internal medicine, family medicine, endocrinology, and cardiology specialties to examine their preference of specialties in managing various domains of CVD prevention. We examined categorical variables using Chi square test and continuous variables using t or analysis of variance test.

Results

Of 956 invitees, 263 from 21 health systems and 9 states responded. Majority of respondents were women (54.5%), practicing physicians (72.5%), specializing in cardiology (43.6%), and working at academic centers (51.3%). Respondents favored all specialties to prescribe statins (43.2%), ezetimibe (37.8%), sodium-glucose cotransporter-2 (SGLT2) inhibitors (30.5%), and aspirin in primary prevention (36.3%). Only 7.9% and 9.5% selected cardiologists and preventive cardiologists, respectively, to prescribe SGLT2 inhibitors. Most preferred specialists (i.e. cardiology and endocrinology) to manage advanced lipid disorders, refractory hypertension, and premature coronary heart disease. The most common conditions selected for preventive cardiologists to manage were genetic lipid disorders (17%), cardiovascular risk assessment (15%), dyslipidemia (13%), and refractory/resistant hypertension (12%).

Conclusions

For CVD prevention practice, providers favored all specialties to manage common conditions, specialists to manage complex conditions, and preventive cardiologists to manage advanced lipid disorders. Cardiologists were least preferred to prescribe SGLT2 inhibitor. Future research should explore reasons for selected CVD prevention practice preferences to optimize care coordination and for effective use of limited expertise.
dc.identifier

7323318

dc.identifier.issn

0032-5473

dc.identifier.issn

1469-0756

dc.identifier.uri

https://hdl.handle.net/10161/29345

dc.language

eng

dc.publisher

Oxford University Press (OUP)

dc.relation.ispartof

Postgraduate medical journal

dc.relation.isversionof

10.1093/postmj/qgad082

dc.subject

cardiovascular prevention

dc.subject

preventive cardiology

dc.title

Specialty preference for cardiovascular prevention practice in the Southeast US and role of a preventive cardiologist.

dc.type

Journal article

duke.contributor.orcid

Bosworth, Hayden B|0000-0001-6188-9825

pubs.begin-page

qgad082

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Medicine, General Internal Medicine

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Center for the Study of Aging and Human Development

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Science & Society

pubs.organisational-group

Population Health Sciences

pubs.organisational-group

Duke Innovation & Entrepreneurship

pubs.organisational-group

Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences

pubs.organisational-group

Duke - Margolis Center For Health Policy

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
qgad082.pdf
Size:
776.85 KB
Format:
Adobe Portable Document Format